Company Filing History:
Years Active: 2005-2009
Title: Michael Belcourt: Innovator in Cancer Treatment
Introduction
Michael Belcourt is a notable inventor based in Wallingford, CT (US), recognized for his contributions to cancer treatment through innovative therapies. With a total of four patents to his name, Belcourt has made significant strides in the field of oncology.
Latest Patents
One of his latest patents is titled "Combination therapy comprising cloretazine." This invention provides a method for treating tumors in subjects by administering an effective amount of VNP40101M, or its equivalent, along with a nucleoside or a nucleoside analog. The invention also outlines a method for inhibiting tumor cell growth by contacting the tumor cells with these effective amounts. Another significant patent is "Compositions and methods for tumor-targeted delivery of effector molecules." This application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for delivering primary effector molecules directly to solid tumors. The invention highlights the surprising discovery that these effector molecules can be delivered locally to tumors with reduced toxicity to the host.
Career Highlights
Michael Belcourt is currently associated with Vion Pharmaceuticals, Inc., where he continues to develop innovative solutions for cancer treatment. His work focuses on creating therapies that enhance the effectiveness of existing treatments while minimizing side effects.
Collaborations
Belcourt has collaborated with notable colleagues such as Ivan C King and David Gordon Bermudes, contributing to the advancement of cancer therapies through shared expertise and innovative ideas.
Conclusion
Michael Belcourt's work in cancer treatment exemplifies the impact of innovation in medicine. His patents reflect a commitment to improving patient outcomes through targeted therapies.